Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton

PLoS ONE

Volumn 3, Issue 7, 2008, Pages

  Fu, Xiao Dong ^a,b   Giretti, Maria S ^a   Baldacci, Chiara ^a   Garibaldi, Silvia ^a   Flamini, Marina ^a   Sanchez, Angel Matias ^a   Gadducci, Angiolo ^a   Genazzani, Andrea R ^a   Simoncini, Tommaso ^a  

^a UNIVERSITY OF PISA   (Italy)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT 13; GUANOSINE TRIPHOSPHATASE; MEDROXYPROGESTERONE ACETATE; MOESIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR A; PROTEIN TYROSINE KINASE; RHO KINASE; RHO KINASE 2; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; ACTIN; ACTIN BINDING PROTEIN; RHOA PROTEIN, HUMAN; ROCK2 PROTEIN, HUMAN;

ACTIN FILAMENT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CELL MIGRATION; CELL MOTION; CONTROLLED STUDY; CYTOSKELETON; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; BREAST TUMOR; DISEASE COURSE; METABOLISM; TUMOR CELL LINE;

ACTINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CYTOSKELETON; DISEASE PROGRESSION; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MICROFILAMENT PROTEINS; NEOPLASM INVASIVENESS; PROGESTERONE; RECEPTORS, PROGESTERONE; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION;

EID: 51349152827     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002790     Document Type: Article

References (51)

1. Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354: 270-282.
2. Giretti MS, Fu XD, De Rosa G, Sarotto I, Baldacci C, et al. (2008) Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS ONE 3: e2238.
3. Lee S Kolonel L, Wilkens L, Wan P, Henderson B, et al. (2006) Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort. Int J Cancer 118: 1285-1291.
4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Jama 288: 321-333.
5. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. Jama 291: 1701-1712
6. Weigelt B, Peterse JL, van't Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5: 591-602.
7. Carragher NO, Frame MC (2004) Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends Cell Biol 14: 241-249.
8. Pawlak G, Helfman DM (2001) Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev 11: 41-47.
9. Louvet-Vallee S (2000) ERM proteins: from cellular architecture to cell signaling. Biol Cell 92: 305-316.
10. Tsukita S, Yonemura S (1999) Cortical actin organization: lessons from ERM (ezrin/radixin/moesin) proteins. J Biol Chem 274: 34507-34510.
11. Oshiro N, Fukata Y, Kaibuchi K (1998) Phosphorylation of moesin by rho-associated kinase (Rho-kinase) plays a crucial role in the formation of microvilli-like structures. J Biol Chem 273: 34463-34666.
12. Simoncini T, Scorticati C, Mannella P, Fadiel A, Giretii MS et al. (2006) Estrogen receptor alpha interacts with Galpha13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway. Mol Endocrinol 20: 1756-1771.
13. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, et al. (2003) Classification and pharmacology of progestins. Maturitas 46 Suppl 1: S7-S16.
14. Stanczyk FZ (2003) All progestins are not created equal. Steroids 68: 879-890.
15. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114: 448-454.
16. Fournier A, Fabre A, Mesrine S, Boultron-Ruault MC, Berrino F, et al. (2008) Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 26: 1260-1268.
17. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, et al. (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. Embo J 9: 1603-1614.
18. Saitoh M, Ohmichi M, Takahashi K, Kawagoe J, Ohta T, et al. (2005) Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/ Akt/nuclear factor-kappaB cascade in human breast cancer cells. Endocrinology 146: 4917-4925.
19. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, et al. (2007) The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol 21: 359-375.
20. Fu XD, Simoncini T (2007) Non-genomic sex steroid actions in the vascular system. Semin Reprod Med 25: 178-186.
21. Simoncini T, Mannella P, Fornari L, Caruso A, Willis MY, et al. (2004) Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 145: 5745-5756.
22. Thomas CP, Liu KZ, Vats HS (2006) Medroxyprogesterone acetate binds the glucocorticoid receptor to stimulate alpha-ENaC and sgkl expression in renal collecting duct epithelia. Am J Physiol Renal Physiol 290: F306-312.
23. Faivre EJ, Lange CA (2007) Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol 27: 466-480.
24. Offermanns S, Mancino V, Revel JP, Simon MI (1997) Vascular system defects and impaired cell chemokinesis as a result of Galpha13 deficiency. Science 275: 533-536.
25. Karteris E, Zervou S, Pang Y, Dong J, Hillhouse EW, et al. (2006) Progesterone signaling in human myometrium through two novel membrane G protein-coupled receptors: potential role in functional progesterone withdrawal at term. Mol Endocrinol 20: 1519-1534.
26. Zhu Y, Bond J, Thomas P (2003) Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor. Proc Natl Acad Sci U S A 100: 2237-2242.
27. Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, et al. (2001) Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell 8: 269-280.
28. Koga F, Xu W, Karpova TS, McNally JG, Baron R, et al. (2006) Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation. Proc Natl Acad Sci U S A 103: 11318-11322.
29. Humphreys RC, Lydon JP, O'Malley BW, Rosen JM (1997) Use of PRKO mice to study the role of progesterone in mammary gland development. J Mammary Gland Biol Neoplasia 2: 343-354.
30. Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus pnogestin. J Natl Cancer Inst 92: 328-332.
31. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, et al. (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. Jama 283: 485-491.
32. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, et al. (2006) Prevention of Brcal-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314: 1467-1470.
33. Vanzulli SI, Soldati R, Meiss R, Colombo L, Molinolo AA, et al. (2005) Estrogen or antiprogestin treatment induces complete regression of pulmonary and axillary metastases in an experimental model of breast cancer progression. Carcinogenesis 26: 1055-1063.
34. Kato S, Pinto M, Carvajal A, Espinoza N, Monso C, et al. (2005) Progesterone increases tissue factor gene expression, procoagulant activity, and invasion in the breast cancer cell line ZR-75-1. J Clin Endocrinol Metab 90: 1181-1188.
35. Hyder SM, Chiappetta C, Stancel GM (2001) Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. Int J Cancer 92: 449-473.
36. Pollard TD, Borisy GG (2003) Cellular motility driven by assembly and disassembly of actin filaments. Cell 112: 453-465.
37. Hughes SC, Fehon RG (2007) Understanding ERM proteins-the awesome power of genetics finally brought to bear. Curr Opin Cell Biol 19: 51-56.
38. Lin VC, Ng EH, Aw SE, Tan MG, Ng EH, et al. (2000) Progesterone induces focal adhesion in breast cancer cells MDA-MB-231 transfected with progesterone receptor complementary DNA. Mol Endocrinol 14: 348-358.
39. Machelon V, Nome F, Grosse B, Lieberherr M (1996) Progesterone triggers rapid transmembrane calcium influx and/or calcium mobilization from endoplasmic reticulum, via a pertussis-insensitive G-protein in granulosa cells in relation to luteinization process. J Cell Biochem 61: 619-628.
40. Lutz LB, Kim B, Jahani D, Hammes SR (2000) G protein beta gamma subunits inhibit nongenomic progesterone-induced signaling and maturation in Xenopus laevis oocytes. Evidence for a release of inhibition mechanism for cell cycle progression. J Biol Chem 275: 41512-41520.
41. Kelly P, Stemmle LN, Madden JF, Fields TA, Daaka Y, et al. (2006) A role for the G12 family of heterotrimeric G proteins in prostate cancer invasion. J Biol Chem 281: 26483-26490.
42. Kelly P, Moeller BJ, Juneja J, Booden MA, Der CJ, et al. (2006) The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis. Proc Natl Acad Sci U S A 103: 8173-8178.
43. Mote PA, Bartow S, Tran N, Clarke CL (2002) Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat 72: 163-172.
44. Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Alfred DC, et al. (2004) Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 10: 2751-2760.
45. McGowan EM, Weinberger RP, Graham JD, Hill HD, Hughes JA, et al. (2003) Cytoskeletal responsiveness to progestins is dependent on progesterone receptor A levels. J Mol Endocrinol 31: 241-253.
46. Graham JD, Yager ML, Hill HD, Byth K, O'Neill GM, et al. (2005) Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. Mol Endocrinol 19: 2713-2735.
47. Saci A, Carpenter CL (2005) RhoA GTPase regulates B cell receptor signaling. Mol Cell 17: 205-214.
48. Haynes MP, Li L, Sinha D, Russell KS, Hisamoto K, et al. (2003) Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. J Biol Chem 278: 2118-2123.
49. Kamps AR, Coffman CR (2005) G protein-coupled receptor roles in cell migration and cell death decisions. Ann N Y Acad Sci 1049: 17-23.
50. Sitruk-Ware R (2003) Progestins in hormonal replacement therapy (HRT): new molecules, risks and benefits. Ann Endocrinol (Paris) 64: 178.
51. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, et al. (2000) Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407: 538-541